A Better Way to Evaluate and Diagnose Asthma and Exercise-Induced Bronchoconstriction (EIB)
Recommended in major guidelines to identify asthma and EIB
Use for Assessment
Use for Management
Learn more about Aridol®
Connect with a Clinical Specialist to schedule your complimentary Education Session (CEU credit options)
Please enter your name and email below.
Focused on every breath
At Methapharm Respiratory we take pride in working with healthcare practitioners to support the right diagnosis for patients exhibiting common respiratory symptoms such as cough, wheeze and shortness of breath. Asthma symptoms are shared across many respiratory conditions and misdiagnosis can easily occur, resulting in patients being placed on ineffective treatments.
Methapharm Respiratory supports clinicians in the diagnostic process with methacholine and mannitol challenge tests as objective measures of airway hyperresponsiveness.
We also offer training and education (CRCE) at no cost.
Aridol® (mannitol inhalation powder)
INDICATION: ARIDOL is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma.
WARNING: RISK OF SEVERE BRONCHOSPASM
Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs it should be treated immediately by administration of a shortacting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV1<1-1.5 liters or <70% of the predicted values) [see Warnings and Precautions (5.1) of the Prescribing Information].
- Aridol package insert, revised 08/2021.
- S. Aaron, K. Vandemheen, et al. Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma. JAMA. 2017 Jan 17;317(3):269-279.
- J. Wager (2016) American Thoracic Society. ATS Pulmonary Function Laboratory Management & Procedure Manual, Third Edition
Aridol® is a registered trademark of Pharmaxis Ltd. 20 Rodborough Rd, Frenchs Forest NSW 2086, Australia. Aridol is distributed by Methapharm, Inc. in the United States.